Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...

Bioequivalence: Overview

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial.

JAMA cardiology·2023

Same author

Transforming Growth Factor-β Analysis of the VANISH Trial Cohort.

Circulation. Heart failure·2023

Same author

A data-driven quality-score system for rating drug products and its implications for the health care industry.

Journal of the American Pharmacists Association : JAPhA·2022

Same author

Ventricular Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy (Analysis Spanning 60 Years Of Practice): AJC Expert Panel.

The American journal of cardiology·2022

Same author

Prognostic value of age-sex adjusted NT-proBNP ratio in obstructive hypertrophic cardiomyopathy.

Progress in cardiovascular diseases·2022

Same author

Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial.

Nature medicine·2021

Same journal

Findings from the 2025 AMCP Foundation Symposium: Health Optimization 2.0.

Journal of managed care & specialty pharmacy·2026

Same journal

AMCP Market Insights: Managed care considerations in Barth syndrome.

Journal of managed care & specialty pharmacy·2026

Same journal

Association between comorbid depression, antidepressant adherence, and disease-modifying therapy adherence among Texas Medicaid patients with sickle cell disease.

Journal of managed care & specialty pharmacy·2026

Same journal

Incremental health care resource utilization, costs, and predictors of high costs in generalized myasthenia gravis.

Journal of managed care & specialty pharmacy·2026

Same journal

Real-world switching and switch-back patterns among patients transitioning from adalimumab to biosimilars in the United States (February 2023 to August 2025).

Journal of managed care & specialty pharmacy·2026

Same journal

The effectiveness and value of B-cell-directed therapies for the treatment of immunoglobulin A nephropathy.

Journal of managed care & specialty pharmacy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Dec 23, 2025

Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care

Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care

Published on: February 16, 2011

A Physician's Perspective on Generic Drug Quality.

Harry M Lever¹

¹Medical Director for the Hypertrophic Cardiomyopathy Clinic at the Cleveland Clinic, Cleveland, Ohio.

Journal of Managed Care & Specialty Pharmacy

|April 30, 2020

Summary

This summary is machine-generated.

This study highlights the critical role of [specific factor] in [specific process], offering new insights into [relevant field]. Further research is needed to fully understand its implications.

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Related Experiment Videos

Last Updated: Dec 23, 2025

Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care

Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care

Published on: February 16, 2011

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Area of Science:

This research falls under the domain of [specific scientific field], focusing on [specific sub-discipline].

Background:

The existing literature on [specific topic] lacks comprehensive data regarding [specific gap].
Understanding [specific factor] is crucial for advancing [relevant application].

Purpose of the Study:

To investigate the impact of [specific factor] on [specific process].
To elucidate the underlying mechanisms of [specific factor]'s influence.

Main Methods:

Utilized [specific methodology] for data collection.
Employed [specific analytical technique] to analyze [type of data].

Main Results:

Observed a significant correlation between [specific factor] and [specific outcome].
Identified [specific pathway] as a key mediator.

Conclusions:

The findings underscore the importance of [specific factor] in [specific process].
This study provides a foundation for future therapeutic strategies targeting [specific condition].